10-Q: Instil Bio Narrows Focus, Extends Cash Runway

Instil Bio, a clinical-stage biopharmaceutical company, reported increased net losses but reduced cash burn from operations, driven by strategic restructuring, a new lead product candidate, and an extended cash runway beyond 2026.

Summary

• Net loss increased to $21.4 million for the three months ended June 30, 2025, and $49.6 million for the six months ended June 30, 2025, compared to $14.9 million and $39.2 million for the same periods in 2024, respectively.
• Accumulated deficit reached $704.7 million as of June 30, 2025.
• Cash, cash equivalents, restricted cash, marketable securities, and long-term investments totaled $103.6 million as of June 30, 2025.
• Cash used in operating activities decreased to $19.0 million for the six months ended June 30, 2025, from $25.0 million for the same period in 2024.
• Received Investigational New Drug (IND) clearance in the United States for a Phase 1 trial of AXN-2510/IMM2510 in relapsed/refractory solid tumors in June 2025, with trial initiation expected before the end of 2025.
• ImmuneOnco, a collaboration partner, announced preliminary Phase 2 data for AXN-2510/IMM2510 in non-small cell lung cancer (NSCLC) in China, showing partial responses in 62% of efficacy evaluable patients as of July 1, 2025.
• A plan to sell the Tarzana facility was approved in March 2025, reclassifying $112.1 million in assets as held for sale, and resulting in a $16.6 million impairment loss for the six months ended June 30, 2025.
• Existing capital is believed to be sufficient to fund operating expenses and capital expenditure requirements beyond 2026, with a potential extension if the Tarzana facility sale is successful.

Sentiment

Score: 6

Explanation: While net losses increased due to strategic investments and impairment charges, the company successfully obtained IND clearance for its lead candidate, reported promising preliminary clinical data from its partner, reduced its operational cash burn, and extended its cash runway beyond 2026. These developments indicate progress on its refocused strategy, though significant risks remain for a clinical-stage biopharmaceutical company.

Positives

• IND clearance for AXN-2510/IMM2510 in the U.S. for a Phase 1 trial in relapsed/refractory solid tumors.
• Preliminary Phase 2 efficacy data from ImmuneOnco's trial in China for AXN-2510/IMM2510 in NSCLC showed a 62% partial response rate in efficacy evaluable patients.
• Cash used in operating activities decreased to $19.0 million for the six months ended June 30, 2025, from $25.0 million in the prior year period, indicating improved operational efficiency.
• Existing cash, cash equivalents, restricted cash, marketable securities, and long-term investments of $103.6 million are expected to fund operations beyond 2026.
• The potential sale of the Tarzana facility could further extend the cash runway.
• Successful at-the-market (ATM) offering raised $6.6 million in net proceeds during Q2 2025, with $93.1 million remaining availability.
• General and Administrative expenses decreased by $7.9 million for the six months ended June 30, 2025, primarily due to reduced headcount and facility costs.

Negatives

• Net loss increased to $49.6 million for the six months ended June 30, 2025, compared to $39.2 million for the same period in 2024.
• Accumulated deficit grew to $704.7 million as of June 30, 2025, indicating continued significant operating losses since inception.
• A significant impairment loss of $16.6 million was recognized for the Tarzana facility during the six months ended June 30, 2025.
• In-process Research and Development (IPR&D) expenses increased by $10.0 million due to a development milestone payment to ImmuneOnco.
• Research and Development (R&D) expenses increased by $1.9 million for the six months ended June 30, 2025, primarily due to ImmuneOnco collaboration activities.
• Has a limited operating history and no history of completing any clinical trial or commercializing any product.
• Reliance on ImmuneOnco for clinical trials in China, with no assurance that data will be accepted by the FDA or other regulatory authorities.

Risks

• Incurred significant losses since inception and expects to incur losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Has a limited operating history and no history of completing clinical trials or commercializing products, making future viability assessment difficult.
• Needs substantial additional funding to meet financial obligations and pursue business objectives; inability to raise capital could delay or curtail development.
• Lead product candidate, AXN-2510/IMM2510, is in early-stage clinical development with high risk of failure.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; failure to obtain approval would substantially harm the business.
• FDA and other foreign regulatory authorities may not accept data from ImmuneOnco's clinical trials conducted in China.
• Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.
• Biologics are complex and difficult to manufacture; reliance on ImmuneOnco and its third-party CDMO in China increases manufacturing risks.
• Strategic transactions to acquire or in-license new product candidates may not be successful.
• Faces significant competition from other biotechnology and pharmaceutical companies.
• Inability to obtain and maintain sufficient patent protection or if the scope of protection is not broad enough, competitors could develop similar products.
• Risk of third parties initiating legal proceedings alleging intellectual property infringement.
• Subject to stringent and evolving U.S. and foreign laws related to data privacy and security; non-compliance could lead to investigations, litigation, fines, and reputational harm.
• Potential for additional losses due to impairment charges, especially if the Tarzana facility sale is unsuccessful or sells for less than carrying value.
• Delays or difficulties in patient enrollment and retention in clinical trials could delay or prevent regulatory approvals.
• Fast Track designation, if sought, may not lead to faster review or approval.
• May expend limited resources on less profitable or less successful product candidates.
• Development of product candidates in combination with other therapies exposes the company to additional regulatory risks.
• Even if approved, products may fail to achieve market acceptance by physicians, patients, and payors.
• Inability to establish sales, marketing, and distribution capabilities could hinder commercialization.
• Treatable populations for product candidates may be smaller than projected.
• Off-label use or misuse of products could harm reputation and lead to liability.
• Competition from biosimilar products could occur sooner than anticipated.
• Success depends significantly on coverage and adequate reimbursement or patient willingness to pay.
• Product liability lawsuits could incur substantial liabilities.
• Reliance on third parties to conduct, supervise, and monitor research and clinical trials.
• Collaboration with ImmuneOnco subjects the company to risks related to U.S.-China relations.
• Ongoing regulatory oversight post-approval may result in significant additional expense.
• Healthcare legislative or regulatory reform measures may negatively impact business.
• Computer system failures, cyberattacks, or cybersecurity deficiencies.
• Failure to comply with environmental, health, and safety laws.
• Dependence on ability to retain key executives and attract/retain qualified personnel.
• Resources may not be sufficient to manage future growth.
• Employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities.
• An active trading market for common stock may not continue to be developed or sustained.
• The trading price of common stock may be volatile, and purchasers could incur substantial losses.
• Limited equity research analyst coverage could cause stock price and trading volume to decline.
• A significant portion of total outstanding shares available for immediate resale could cause the market price of common stock to drop significantly.
• Provisions in corporate charter documents and under Delaware law may prevent or frustrate attempts by stockholders to change management.
• Concentration of ownership among existing executive officers, directors, and principal stockholders may prevent new investors from influencing significant corporate decisions.
• As an emerging growth company and a smaller reporting company, reduced disclosure and governance requirements may make common stock less attractive to investors.
• Has broad discretion in the use of cash and cash equivalents, which may not yield a return on investment.
• Does not anticipate paying any cash dividends on common stock in the foreseeable future, making capital appreciation the sole source of gains.
• Amended and restated certificate of incorporation provides exclusive forums for disputes, which could limit stockholders' ability to obtain a favorable judicial forum.
• Incurs and will continue to incur increased costs and demands upon management as a public company.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate financial statements on a timely basis.
• Effective tax rate may fluctuate, and obligations in tax jurisdictions may exceed accrued amounts.
• Might not be able to utilize a significant portion of net operating loss carryforwards due to ownership changes.
• Business activities will be subject to the Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws.
• Disruptions at the FDA and other government agencies caused by funding shortages, layoffs, shifting priorities, or global health concerns could hinder their ability to perform normal business functions.
• Unfavorable global economic and political conditions could adversely affect business, financial condition, or results of operations.
• Non-U.S. holders of common stock may be subject to U.S. federal income tax if the company is considered a United States real property holding corporation.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future. Development efforts are focused on advancing AXN-2510/IMM2510, with a Phase 1 trial in the U.S. expected to initiate before the end of 2025. The company may pursue additional therapeutic in-licensing or acquisition opportunities. Existing capital is believed to be sufficient to fund operations beyond 2026, with a potential extension if the Tarzana facility sale is successful. Future expenditures are expected to be significant due to R&D, clinical trials, regulatory approvals, potential commercialization, personnel, intellectual property, and public company operating costs.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report."
• "We expect to continue to incur net losses for the foreseeable future."
• "Our development efforts are focused on advancing AXN-2510/IMM2510 and we may pursue additional promising therapeutic in-licensing or acquisition opportunities."
• "Based on our current operating plan, we believe our existing cash, cash equivalents, restricted cash, marketable securities and long-term investments will be sufficient to fund our operating expenses and capital expenditure requirements beyond 2026."
• "If we are successful in selling the Tarzana facility, such a transaction could potentially extend our expected cash runway."

Industry Context

The biopharmaceutical industry is highly competitive and subject to rapid technological advancements, particularly in oncology. Instil Bio operates in the immuno-oncology space, targeting solid tumor cancers with bispecific antibodies. The market for non-small cell lung cancer (NSCLC) treatments is crowded with established therapies (chemotherapy, immunotherapy, hormone therapy, surgery, radiation) and numerous competitors developing novel compounds, including other immuno-oncology drugs and targeted therapies. The company's lead candidate, AXN-2510/IMM2510, is a PD-L1xVEGF bispecific antibody, a mechanism that competes with existing PD-L1 inhibitors and VEGF inhibitors, as well as combination therapies. The industry faces increasing governmental scrutiny on pharmaceutical pricing and evolving regulatory landscapes, such as the Inflation Reduction Act and Project Optimus, which could impact drug development and commercialization.

Comparison to Industry Standards

• The company's lead candidate, AXN-2510/IMM2510, is a PD-L1xVEGF bispecific antibody, competing with established immuno-oncology drugs like pembrolizumab (Keytruda, Merck), atezolizumab (Tecentriq, Genentech/Roche), nivolumab (Opdivo, Bristol Myers Squibb), and durvalumab (Imfinzi, AstraZeneca), which target PD-L1 or PD-1.
• It also competes with anti-angiogenic therapies like bevacizumab (Avastin, Genentech/Roche) and ramucirumab (Cyramza, Eli Lilly) that target VEGF.
• Preliminary Phase 2 data for AXN-2510/IMM2510 in NSCLC from ImmuneOnco's China trial showed a 62% partial response rate (PR) in efficacy evaluable patients (80% in squamous NSCLC, 46% in non-squamous NSCLC). This compares to overall response rates (ORR) of 45-60% seen in various trials for Keytruda plus chemotherapy in first-line advanced NSCLC, depending on PD-L1 expression and histology.
• Other bispecific antibodies or novel combinations in development for NSCLC include Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan and Johnson & Johnson's amivantamab and lazertinib, which have reported Phase 3 data.
• The significant accumulated deficit of $704.7 million and continued net losses are typical for clinical-stage biopharmaceutical companies that have not yet commercialized products.
• The cash runway 'beyond 2026' is a reasonable outlook for a company at this stage, especially with ongoing strategic asset sales and capital raising efforts (ATM program).

Stakeholder Impact

• Shareholders: Potential for dilution from ATM program; stock price volatility; long-term value dependent on successful product development and commercialization; no dividends expected.
• Employees: Workforce reductions due to restructuring plans (2023 and 2024 Plans) in the UK; continued competition for attracting and retaining qualified scientific and clinical personnel.
• Customers (future): Potential for new treatment options for solid tumor cancers, particularly NSCLC, if AXN-2510/IMM2510 is successfully developed and commercialized.
• Suppliers/Creditors: Continued reliance on third-party manufacturers and CROs; loan obligations to Midland National Life Insurance Company.
• Regulatory Authorities: Ongoing interactions with FDA for INDs and future approvals; compliance with evolving healthcare laws and regulations.

Next Steps

• Initiate a Phase 1 trial of AXN-2510/IMM2510 as monotherapy for patients with relapsed/refractory solid tumors in the U.S. before the end of 2025.
• ImmuneOnco to continue Phase 1 and Phase 2 clinical trials of AXN-2510/IMM2510 in China.
• Potentially pursue additional promising therapeutic in-licensing or acquisition opportunities.
• Seek to complete the sale of the Tarzana facility.
• Continue to incur significant expenses for R&D, clinical trials, regulatory approvals, and potential commercialization.
• Potentially raise additional capital through equity offerings, debt financings, or strategic collaborations.

Key Dates

Recommendation

Instil Bio is undergoing a significant strategic pivot, evidenced by the divestiture of its Tarzana facility and a sharpened focus on its in-licensed bispecific antibody, AXN-2510/IMM2510. The IND clearance for AXN-2510/IMM2510 in the U.S. and promising preliminary Phase 2 data from China are positive clinical milestones, suggesting potential for the new lead candidate. Furthermore, the company has extended its cash runway beyond 2026, providing crucial financial stability for ongoing development. However, the company continues to incur substantial net losses and operates in a high-risk, competitive clinical-stage biopharmaceutical environment with no commercialized products. The increased net loss and impairment charges reflect the costs of this transition. Given the early stage of the lead program and the inherent uncertainties of drug development, a "hold" recommendation is appropriate. Investors should monitor the progress of AXN-2510/IMM2510's clinical trials and the successful execution of the Tarzana facility sale.

Keywords

Biopharmaceutical, Oncology, Solid Tumors, AXN-2510, IMM2510, PD-L1, VEGF, Bispecific Antibody, Clinical Stage, Drug Development, Cancer Therapy, Biotechnology, Pharmaceutical, Clinical Trials, Corporate Restructuring, Asset Sale, Cash Runway, Capital Raise